However, this experiment does not reflect the actual clinical situation, because EGFR-TKIs are usually prescribed to patients with EGFR mutation, and most EGFR-mutated lung cancers are adenocarcinomas. The gene discussed is EGFR; the disease is adenocarcinoma.